Efficacy News and Research

RSS

Non-aspirin pain drugs may help men with recurrent prostate cancer

Early results from a University of North Carolina at Chapel Hill School of Medicine study may determine if drugs called Cox-2 inhibitors, a newer type of non-aspirin pain medicine now widely prescribed for arthritis symptoms, may benefit men with recurrent prostate cancer.

10 Jun 2004

Discovery could pave the way to smallpox Immunity

A team of scientists led by a Howard Hughes Medical Institute (HHMI) international research scholar has discovered the immune system mechanism that causes some mice to be more susceptible to mousepox than others.

9 Jun 2004

Market research - European Electronic Medical Records

The overwhelming need for cost-effective and high-quality healthcare delivery is motivating the implementation of IT solutions such as the electronic medical records (EMR) system.

9 Jun 2004

Many epilepsy and multiple sclerosis patients believe marijuana is an effective treatment

Despite limited evidence of effectiveness, many epilepsy and multiple sclerosis patients believe marijuana is an effective treatment and are actively using it, according to two Canadian studies published in the June 8 issue of Neurology, the scientific journal of the American Academy of Neurology.

9 Jun 2004

Investigational drug, LAF237 improved glycemic control in patients with type 2 diabetes

Research presented today showed that the investigational drug, LAF237, the first in a new class, improved glycemic control in patients with type 2 diabetes. In this study, LAF237, which is administered as a tablet to be taken orally, was added to the standard diabetes treatment metformin in patients whose diabetes was not adequately controlled by metformin alone.

7 Jun 2004

Velcade major improvement over standard therapy for relapsed multiple myeloma

Early results from a major, international Phase III clinical trial decisively show that recurrent multiple myeloma is more effectively treated with the drug bortezomib (trade name: Velcade TM) than with dexamethasone, a drug that for decades has been the standard therapy for relapsed disease, researchers at Dana-Farber Cancer Institute report.

6 Jun 2004

Antipsychotic compound bifeprunox worth USD 1 billion per year to Solvay and Wyeth

Solvay has re-evaluated the commercial potential of bifeprunox, a Solvay compound in clinical development for the treatment of schizophrenia . Bifeprunox additionally has the potential to be developed in other disorders, i.e. bipolar disorder.

3 Jun 2004

Study may help oncologists tailor chemotherapy to patients based on their genetic make-up

Genetic variations in an individual’s ability to repair DNA damage may help predict survival in lung cancer patients treated with the common chemotherapy drugs cisplatin or carboplatin, a new study shows.

2 Jun 2004

Research laboratory at the forefront of the science of metabolomics

A new $1.8 million research laboratory will catapult Iowa State University to the forefront of the science of metabolomics.

2 Jun 2004

BioSante publishes oral insulin study

BioSante Pharmaceuticals, Inc. has announced the publication of positive results of a preclinical study of its proprietary calcium phosphate nanoparticle (CAP) delivery system for the oral delivery of insulin in the June 11 issue of the peer-reviewed International Journal of Pharmaceutics.

2 Jun 2004

Prescribing ACE inhibitors to in-patients is important, but outpatients need ongoing support

Use of angiotensin-converting enzyme (ACE) inhibitors by heart failure patients drops sharply within a month after they go home from the hospital and then continues to decline, according to a new study in the June 2, 2004 issue of the Journal of the American College of Cardiology.

2 Jun 2004

Where you live may increase risk factors for asthma

Along with the usual risk factors for asthma such as smoking and poverty, researchers have added another factor that may contribute: a neighborhood where people live in fear.

1 Jun 2004

Treatment helps 26% of black Americans with chronic hepatitis C

Twenty-six percent (26%) of black Americans (BA) with chronic hepatitis C who received treatment with Pegasys plus Copegus (peginterferon alfa-2a plus ribavirin) achieved a sustained virological response (SVR), according to study results published in the June 2004 issue of Hepatology.

1 Jun 2004

Weight loss medication Xenical® more effective than lifestyle changes alone in managing weight

The weight loss medication Xenical® (orlistat) has been shown to be significantly more effective than lifestyle changes alone in managing weight in overweight adolescents, according to new study results presented today at ECO2004, Prague, Czech Republic.

27 May 2004

New study challenges current thinking about varied response to hepatitis C treatment in different racial groups

Results of a new study published in the current issue of the New England Journal of Medicine show that in patients who have chronic hepatitis C, genotype 1 -- the most common form of the disease and difficult to treat successfully -- non-Hispanic whites achieved one of the highest response rates reported to date, but response rates in African Americans were significantly lower.

27 May 2004

Research tests the efficacy of a smallpox vaccine candidate known as LC16m8

When used as an aerosolized weapon, smallpox could be controlled by a new vaccine under study at Saint Louis University School of Medicine, according to new data.

27 May 2004

MDA researchers find creatine helps in Duchenne dystrophy

Grip strength in the dominant hand and fat-free body mass (made mostly of muscle) increased when children with Duchenne muscular dystrophy (DMD) took the dietary supplement creatine at a dose of 0.1 grams per kilogram of body weight per day for four months.

25 May 2004

Focus on implantation of artificial discs to treat degenerative disc disease

Implantation of artificial discs to treat degenerative disc disease was the subject of multiple presentations earlier this month at the Spine Arthroplasty Meeting in Vienna, Austria, where spine and orthopaedic surgeons from all over the world heard new data about this technology.

25 May 2004

Zengen announces positive results of treatment for vaginal yeast infection

Zengen Inc. announced today positive phase I/II results for its proprietary molecule CZEN-002 for the treatment of vulvovaginal candidiasis (VVC), commonly known as vaginal yeast infection.

25 May 2004

Weekly cycles of once-daily anti-HIV drugs could reduce cost of HIV treatment

In a small study conducted at the U.S. National Institutes of Health (NIH), researchers have shown that it may be feasible to treat HIV-infected patients with a simple, once-daily regimen of anti-HIV drugs given in pre-planned, 7-day-on, 7-day-off cycles.

24 May 2004